ABG
MDGL icon

Ally Bridge Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Ally Bridge Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,662
Closed -$15M – 24
2025
Q3 		$15M Buy
+32,662
New +$12.2M 9.12% 4
2023
Q2 		– Sell
-29,614
Closed -$7.17M – 19
2023
Q1 		$7.17M Buy
+29,614
New +$8.07M 9.4% 5

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ally Bridge Group's MDGL Position: Q4 2025 in Review

Ally Bridge Group sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 32,662 shares — an estimated $15M sold.

Ally Bridge Group first reported a position in MDGL in Q1 2023 and held it in 2 quarters. The position peaked at $15M in Q3 2025. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • Ally Bridge Group reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Ally Bridge Group sold 32,662 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $15M.
  • Ally Bridge Group first reported a position in Madrigal Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Ally Bridge Group's Madrigal Pharmaceuticals position peaked at $15M in Q3 2025.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on Ally Bridge Group's 13F filing for Q4 2025, filed 17 Feb 2026.